Topical cyclosporin A in the treatment of anterior segment inflammatory disease.
Topical cyclosporin A was used in the management of 43 patients with a variety of anterior segment inflammatory disorders that had failed corticosteroid treatment. Treatment with topical cyclosporin A ranged from 1 week to 43 months, with a mean treatment period of 13 months. Thirty-five patients (81%) with disorders including high-risk keratoplasty, atopic and vernal keratoconjunctivitis, ligneous conjunctivitis, ulcerative keratitis, and Mooren's ulcer had a beneficial result, with resolution, reduction, or prevention of inflammation. Six patients (14%) with scleritis, ocular cicatricial pemphigoid, or endothelitis showed no clinical improvement. Two patients (5%) had significant ocular discomfort, and the drug had to be discontinued in them. None of the other patients developed local side effects. Twenty-seven of these patients were followed with serial cyclosporin A blood levels and serum creatinine. None of these patients developed measurable drug blood levels or renal toxicity.
Holland
E J
EJ
Department of Ophthalmology, University of Minnesota, Minneapolis 55455.
Olsen
T W
TW
Ketcham
J M
JM
Florine
C
C
Krachmer
J H
JH
Purcell
J J
JJ
Lam
S
S
Tessler
H H
HH
Sugar
J
J
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000869:Anterior Eye Segment / Q000187:drug effects*; D002648:Child; D002675:Child, Preschool; D003315:Cornea / Q000187:drug effects; D016572:Cyclosporine / Q000008:administration & dosage* / Q000627:therapeutic use; D009877:Endophthalmitis / Q000188:drug therapy*; D005260:Female; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D015948:Keratoplasty, Penetrating; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions
D009883:Ophthalmic Solutions; D016572:Cyclosporine